{"product_id":"elekta-five-forces-analysis","title":"Elekta Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFrom Overview to Strategy Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eElekta faces moderate rivalry with high switching costs and strong buyer expectations, while supplier power and regulatory barriers limit new entrants; substitutes and tech disruption pose evolving threats to its oncology-focused portfolio. This brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Elekta’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized High-Tech Components\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe production of Elekta linear accelerators and radiosurgery systems depends on specialized parts like magnetrons and digital detectors, and only a few global suppliers meet medical-grade precision; in 2024, top 5 vendors supplied ~70% of critical imaging\/delivery components, raising supplier leverage.\u003c\/p\u003e\n\u003cp\u003eScarcity plus 2021–2023 supply disruptions pushed component lead times from ~12 to 20+ weeks and supplier-driven price increases of 8–15%, so suppliers can affect Elekta pricing and delivery.\u003c\/p\u003e\n\u003cp\u003eElekta therefore maintains strategic partnerships, long-term contracts, and dual-sourcing for critical parts to secure supply; inventory-to-sales targets rose to ~2.5 months in 2024 to buffer volatility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSoftware and AI Development Talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs oncology shifts to data-driven, personalized care, Elekta’s reliance on software and AI talent grows; the global AI talent market saw 650,000 core specialists in 2024, with demand up ~35% year-over-year, giving these suppliers high bargaining power.\u003c\/p\u003e\n\u003cp\u003eElekta must invest heavily in hiring and retention to keep MOSAIQ and Monaco competitive—R\u0026amp;D spend was SEK 1.6bn in 2024—because talent shortages can delay roadmaps and slow innovation cycles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRare Isotopes and Raw Materials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBrachytherapy and some radiosurgery devices rely on radioisotopes (e.g., Ir-192, Cs-137) and tungsten; global supply is concentrated—few producers control \u0026gt;70% of medical-grade isotopes and China supplies ~80% of tungsten refining as of 2025—so suppliers wield strong bargaining power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Diagnostic Imaging Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eElekta integrates third-party MRI\/CT modules into its systems, creating dependency on large imaging firms that control complex, certified sub-systems; top suppliers like Siemens Healthineers, GE Healthcare, and Philips held ~60–70% share of the diagnostic imaging market in 2024. \u003c\/p\u003e\n\u003cp\u003eIf a partner shifts strategy or raises prices, Elekta’s margins can compress—FY2024 gross margin 39.8% leaves limited buffer versus higher component costs. \u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDependency on few suppliers\u003c\/li\u003e\n\u003cli\u003eHigh regulatory integration cost\u003c\/li\u003e\n\u003cli\u003eMarket share concentration ~60–70%\u003c\/li\u003e\n\u003cli\u003eFY2024 gross margin 39.8%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Compliance Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSuppliers of clinical trial management and regulatory consulting hold strong bargaining power because their expertise is essential for market access; global regulatory complexity rose 18% in filings 2024–25, raising demand for niche consultants.\u003c\/p\u003e\n\u003cp\u003eElekta depends on these specialists to meet FDA and EMA standards; a single major compliance failure can cost $100M+ in recalls and delays, so providers charge premium rates.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEssential service drives leverage\u003c\/li\u003e\n\u003cli\u003eRegulatory filings up 18% (2024–25)\u003c\/li\u003e\n\u003cli\u003eNon-compliance can exceed $100M loss\u003c\/li\u003e\n\u003cli\u003eSpecialists command higher fees\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier Concentration and Long Lead Times Squeeze Elekta’s Margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold high bargaining power for Elekta due to concentration in critical components (top 5 vendors ≈70% of parts, 2024), long lead times (12→20+ weeks post-2021), commodity dependence (China ≈80% tungsten refining, 2025), and talent scarcity (650k AI specialists, +35% y\/y, 2024); FY2024 gross margin 39.8% limits price absorption.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop-5 supplier share\u003c\/td\u003e\n\u003ctd\u003e~70% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eComponent lead time\u003c\/td\u003e\n\u003ctd\u003e20+ weeks (post-2021)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWolfram (tungsten) refining\u003c\/td\u003e\n\u003ctd\u003eChina ~80% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI specialists\u003c\/td\u003e\n\u003ctd\u003e650,000, +35% y\/y (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 gross margin\u003c\/td\u003e\n\u003ctd\u003e39.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces analysis of Elekta that uncovers competitive dynamics, supplier and buyer power, threats from substitutes and new entrants, and strategic levers to protect market share and profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Elekta Porter's Five Forces snapshot—tailored to med‑tech dynamics—to quickly show competitive intensity and strategic levers for clinical, regulatory, and supplier pressures.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital System Consolidation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe 2024 consolidation of US hospitals left the top 10 health systems controlling ~30% of hospital beds, and large Integrated Delivery Networks now account for roughly 40% of Elekta’s revenue, giving buyers scale to demand double-digit discounts on device pricing.\u003c\/p\u003e\n\u003cp\u003eCentralized procurement teams, using competitive RFPs and total-cost-of-ownership analyses, routinely pit suppliers against each other, pressuring Elekta’s margins and pushing the company to sell bundled, value-based care solutions tied to outcomes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Healthcare Tenders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn many European and emerging markets governments buy most medical tech via tenders, and public contracts often cover 50–80% of hospital capital spend; these tenders prioritize cost-effectiveness and 5–10 year service agreements, pressuring upfront price and lifecycle revenue. Losing a single multi-year tender (typical value €10–150m regionally) can cut regional market share by several percentage points and reduce recurring service revenue. That scale gives health ministries strong leverage on product specs, warranty terms, and bundled pricing, forcing Elekta to accept tighter margins or custom configurations to win.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Switching Costs and Ecosystem Lock-in\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuyers hold leverage at purchase, but high switching costs deter churn: replacing Elekta’s radiotherapy suite typically costs hospitals $3–10M in equipment plus 6–12 months of retraining, per vendor migration case studies in 2023–2024.\u003c\/p\u003e\n\u003cp\u003eTraining staff on Elekta’s Unity\/Mosaiq software and proprietary hardware creates data migration and clinical downtime risks, so hospitals often stay put after go-live.\u003c\/p\u003e\n\u003cp\u003eThat ecosystem lock-in shields Elekta’s recurring revenues and service contracts, but initial contracts are fiercely contested by Varian and others, with procurement bids often deciding multi-year market share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDemand for Proven Clinical Outcomes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHealthcare providers demand evidence-based results; in 2024, 78% of US hospitals cited clinical outcomes as top purchase criteria, so buyers press Elekta for peer-reviewed studies showing improved survival or throughput.\u003c\/p\u003e\n\u003cp\u003eIf rivals publish stronger evidence, hospitals switch quickly despite brand history, forcing Elekta to spend on trials—Elekta invested SEK 1.2bn in R\u0026amp;D in 2024 to defend clinical claims.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math: higher-quality trials cut sales cycle time by ~25%, so weak data raises churn and pricing pressure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e78% of US hospitals prioritize outcomes (2024)\u003c\/li\u003e\n\u003cli\u003eElekta R\u0026amp;D SEK 1.2bn (2024)\u003c\/li\u003e\n\u003cli\u003eBetter trials ≈ 25% shorter sales cycles\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBudgetary Constraints and Reimbursement Rates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe financial health of hospitals and clinics depends heavily on government and insurer reimbursement rates for radiation therapy; Medicare cutbacks of 3.5% to radiation oncology packs in 2024 tightened capital budgets nationwide.\u003c\/p\u003e\n\u003cp\u003eWhen reimbursement falls, buyers postpone purchases of high-cost systems like Elekta Unity, favor refurbished units, or extend legacy-system lifecycles, raising price sensitivity and elongating sales cycles.\u003c\/p\u003e\n\u003cp\u003eElekta must offer flexible financing, outcome-based pricing, and transparent ROI models—typical payback targets: 3–5 years—to win deals amid constrained cash flow.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMedicare 2024 cut ~3.5% in some radiotherapy payments\u003c\/li\u003e\n\u003cli\u003eHospitals target 3–5 yr ROI for imaging\/radiation buys\u003c\/li\u003e\n\u003cli\u003eRefurbished market share rose ~7% YoY in 2023\u003c\/li\u003e\n\u003cli\u003eFlexible financing and outcome pricing reduce purchase friction\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElekta squeezed by buyer leverage, but high switching costs and outcomes drive R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuyers (large US systems, govts) wield strong price leverage via consolidation and tenders, squeezing Elekta’s margins, but high switching costs ($3–10M, 6–12 months) and product lock-in protect recurring service revenue; clinical evidence (78% of US hospitals cite outcomes) and reimbursement cuts (Medicare −3.5% in 2024) force Elekta to invest (SEK 1.2bn R\u0026amp;D 2024) in trials, financing, and outcome-based deals.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS hospitals prioritizing outcomes\u003c\/td\u003e\n\u003ctd\u003e78%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eElekta R\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eSEK 1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSwitching cost (equip+retrain)\u003c\/td\u003e\n\u003ctd\u003e$3–10M; 6–12m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare radiotherapy cuts\u003c\/td\u003e\n\u003ctd\u003e−3.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eElekta Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Elekta Porter's Five Forces analysis you'll receive immediately after purchase—no placeholders, no mockups. The document displayed is the final, professionally formatted file, ready for download and use the moment you buy. It contains the complete competitive assessment, actionable insights, and supporting evidence as shown here. You're getting this identical deliverable upon payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747222270329,"sku":"elekta-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/elekta-five-forces-analysis.png?v=1772196154","url":"https:\/\/matrixbcg.com\/products\/elekta-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}